Progyny, Inc. (NASDAQ:PGNY) CEO Peter Anevski Purchases 209,500 Shares

Progyny, Inc. (NASDAQ:PGNY) CEO Peter Anevski bought 209,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now owns 441,463 shares of the company’s stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Progyny Price Performance

NASDAQ:PGNY traded up $0.18 during trading hours on Thursday, reaching $14.71. 1,918,778 shares of the company were exchanged, compared to its average volume of 1,423,054. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 1.64 and a beta of 1.35. The stock has a 50 day simple moving average of $15.27 and a 200 day simple moving average of $20.63. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08.

Progyny (NASDAQ:PGNY) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same quarter in the previous year, the firm posted $0.16 EPS. The business’s revenue was up 2.0% compared to the same quarter last year. On average, analysts predict that Progyny, Inc. will post 0.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on PGNY shares. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $17.00 target price (down previously from $22.00) on shares of Progyny in a research note on Monday, December 2nd. Bank of America cut their price target on shares of Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 target price on shares of Progyny in a research report on Tuesday, October 1st. Truist Financial reissued a “hold” rating and set a $19.00 price objective (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Finally, Canaccord Genuity Group dropped their target price on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a report on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $25.00.

Institutional Trading of Progyny

Large investors have recently modified their holdings of the business. Pacer Advisors Inc. lifted its position in shares of Progyny by 12,579.4% during the third quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company’s stock worth $41,777,000 after purchasing an additional 2,472,983 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in Progyny by 1,576.0% in the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company’s stock worth $42,991,000 after acquiring an additional 2,412,068 shares during the last quarter. Invenomic Capital Management LP acquired a new position in Progyny in the third quarter valued at approximately $29,509,000. Farallon Capital Management LLC boosted its position in Progyny by 120.8% during the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock valued at $37,436,000 after purchasing an additional 715,900 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Progyny by 530.4% during the third quarter. Barclays PLC now owns 706,157 shares of the company’s stock valued at $11,835,000 after acquiring an additional 594,140 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.